Text Size

Effect of NAC on Sleep Apnea

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2007 by Assaf-Harofeh Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Assaf-Harofeh Medical Center
ClinicalTrials.gov Identifier:
NCT00592618
First received: January 1, 2008
Last updated: January 11, 2008
Last verified: May 2007
History of Changes
  Purpose

Sleep studies in ESRD patients have identified increased prevalence of Sleep Apnea. Based on current knowledge, treatment aimed at reducing oxidative stress might improve Sleep Apnea in HD patients. The aim of our study is to investigate the effect of N-acetylsysteine on Sleep Apnea in HD patients.


Condition Intervention
ESRD
Sleep Apnea
 Drug: Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Sleep Apnea
U.S. FDA Resources

Further study details as provided by Assaf-Harofeh Medical Center:

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   20 Years to 85 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • The study will include 20 patients with ESRD, treated with chronic hemodialysis in Assaf Harofeh Medical Center and suffering from sleep disturbances, such as frequent arousals, snoring, daytime sleepiness.

Exclusion Criteria:

Patients will be excluded from the study if they are:

  • Recently started treated with chronic dialysis: less than 3 months.
  • Survived recent major illness, requiring hospitalisation in the last 3 months.
  • Patients with acute renal failure
  • Currently treated with antioxidants ( NAC, vitamin E ets.)
  • Current use of sleep pills
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00592618

Contacts
Contact: Leonid S Feldman, MD +972-8-9779383 leonidf@asaf.health.gov.il

Locations
Israel
Nephrology Division, Assaf Harofeh Medical Center Not yet recruiting
Zerifin, Israel, 70300
Contact: Leonid S Feldman     +972-8-9779383     leonidf@asaf.health.gov.il    
Sponsors and Collaborators
Assaf-Harofeh Medical Center
Investigators
Principal Investigator: Leonid S Feldman, MD Assaf Harofeh MC
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00592618     History of Changes
Other Study ID Numbers: 346147SLEEP
Study First Received: January 1, 2008
Last Updated: January 11, 2008
Health Authority: Israel: Ministry of Health

Keywords provided by Assaf-Harofeh Medical Center:
ESRD
Hemodialysis
Sleep Apnea

Additional relevant MeSH terms:
Apnea
Kidney Failure, Chronic
Sleep Apnea Syndromes
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Renal Insufficiency, Chronic
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Disorders
Nervous System Diseases
 Acetylcysteine
N-monoacetylcystine
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Expectorants
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antidotes

ClinicalTrials.gov processed this record on May 22, 2013